Amneal Secures 505(b)(2) NDA Approval From FDA For PEMRYDI RTU, A Ready-To-Use Oncology Injectable
Portfolio Pulse from Benzinga Newsdesk
Amneal Pharmaceuticals has secured FDA approval for PEMRYDI RTU, a ready-to-use oncology injectable. The product is the first of its kind and does not require reconstitution, dilution, or refrigeration. It will be available in three vial sizes and is expected to launch in Q1 2024.
June 14, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amneal Pharmaceuticals' FDA approval for PEMRYDI RTU, a ready-to-use oncology injectable, may boost the company's market position and revenue.
The FDA approval for PEMRYDI RTU is a significant milestone for Amneal Pharmaceuticals (AMRX) as it is the first and only ready-to-use presentation of pemetrexed for injection. This unique product offering may give the company a competitive edge in the oncology market and potentially increase its revenue once the product is launched in Q1 2024.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100